



#12C/RW  
05-20-03

Patent Docket P0978P3C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  Ashkenazi et al.  Serial No.: 09/479,252  Filed: January 7, 2000  For: Apo-2 Ligand  Confirmation No. 2825	Group Art Unit: 1647  Examiner: B. Bunner
--	---

RECEIVED

MAY 16 2003

RESPONSE

TECH CENTER 1600/2900

This paper is being filed in response to the office action mailed November 13, 2002. Entry of the amendment and consideration of the remarks herein are respectfully requested.

IN THE SPECIFICATION:

In the paragraph on page 1, lines 12-18, the text has been amended to read as follows:

---This application is a continuation of application serial no. 09/060,533 filed April 15, 1998, now abandoned, which is a continuation-in-part application of application serial no. 09/007,886 filed January 15, 1998, now abandoned, which is a continuation-in-part application of application serial no. 08/780,496 filed January 8, 1997, now issued as US Patent No. 6,046,048, which is a non-provisional application claiming priority under 35 USC 119(e) to provisional application no. 60/009,755 filed January 9, 1996, the contents of which are incorporated herein by reference. ---

IN THE CLAIMS:

1. (Amended) An isolated soluble Apo-2 ligand polypeptide comprising amino acid residues 91-281 of Figure 1A (SEQ ID NO:1).